DSG2 and chronic myelogenous leukemia, BCR-ABL1 positive: As many cancers with hematopoietic cell origin show strongly upregulated DSG2 expression and present a potential target for oncolytic viral therapy [15], we also tested the transgene expression of our novel JO4 vectors in K562 (chronic myeloid leukemia) and Jurkat (acute T cell leukemia) cells.